• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • Patient Education
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Directories » FDA Approved Drugs » Cresemba (isavuconazonium sulfate)

AND
  • A
  • B
  • C
  • D
  • E
  • F
  • G
  • H
  • I
  • J
  • K
  • L
  • M
  • N
  • O
  • P
  • Q
  • R
  • S
  • T
  • U
  • V
  • W
  • X
  • Y
  • Z

Cresemba (isavuconazonium sulfate)

  • Profile

Profile

Contact Information

Currently Enrolling Trials

    Show More

    General Information

    Cresemba (isavuconazonium sulfate) is an azole antifungal.

    Cresemba is specifically indicated for patients 18 years of age and older for the treatment of invasive aspergillosis and invasive mucormycosis.

    Cresemba is supplied as a solution for intravenous infusion and as a capsule for oral administration. The recommended dose is as follows:

    Cresemba injection:

    Loading dose: 1 reconstituted vial (372 mga ) intravenously every 8 hours for 6 doses (48 hours) 

    Maintenance dose: 1 reconstituted vial (372 mga ) intravenously once daily

    Cresemba capsules:

    Loading dose: 2 capsules (372 mga ) orally every 8 hours for 6 doses (48 hours) 

    Maintenance dose: 2 capsules (372 mga ) orally once daily 

    Clinical Results

    FDA Approval

    The FDA approval of Cresemba was based on the following trials:

    Invasive Aspergillus

    Trial 1 was a randomized, double-blind, non-inferiority active controlled trial which evaluated the safety and efficacy of Cresemba versus voriconazole for primary treatment of invasive fungal disease caused by Aspergillus species or other filamentous fungi. Patients randomized to receive Cresemba treatment were administered a loading dose intravenously of 372 mg of isavuconazonium sulfate (equivalent to 200 mg of isavuconzole) every 8 hours for the first 48 hours. Beginning on day 3, patients received intravenous or oral therapy of 372 mg of isavuconazonium sulfate (equivalent to 200 mg of isavuconazole) once daily. Patients randomized to receive voriconazole treatment were administered voriconazole intravenously with a loading dose of 6 mg/kg every 12 hours for the first 24 hours followed by 4 mg/kg intravenously every 12 hours for the following 24 hours. Therapy could then be switched to an oral formulation of voriconazole at a dose of 200 mg every 12 hours. In this trial, the protocol-defined maximum treatment duration was 84 days. Mean treatment duration was 47 days for both treatment groups, of which 8 to 9 days was by an intravenous route of administration. All-cause mortality through Day 42 in the overall population (ITT) was 18.6% in the Cresemba treatment group and 20.2% in the voriconazole treatment group for an adjusted treatment difference of -1.0% with 95% confidence interval of -8.0% to 5.9%. Similar results were seen in patients with proven or probable invasive aspergillosis confirmed by serology, culture or histology.

    Invasive Mucormycosis

    This open-label non-comparative trial evaluated the safety and efficacy of a subset of patients with invasive mucormycosis. Thirty-seven (37) patients had proven or probable mucormycosis. Patients were treated with Cresemba intravenously or via oral administration at the recommended doses. Median treatment duration was 102 days for patients classified as primary, 33 days for refractory, and 85 days for intolerant. The trial compared treatment with Cresemba with the natural disease progression associated with untreated mucormycosis. Cresemba was safe and effective. However, the efficacy of Cresemba for the treatment for invasive mucormycosis has not been evaluated in concurrent, controlled clinical trials. 

    Side Effects

    Adverse effects associated with the use of Cresemba may include, but are not limited to, the following:

    • nausea
    • vomiting
    • diarrhea
    • headache
    • abnormal liver blood tests
    • hypokalemia
    • constipation
    • dyspnea
    • coughing
    • peripheral edema

    Cresemba may also cause serious side effects including liver problems, infusion reactions and severe allergic and skin reactions.

    Mechanism of Action

    Cresemba (isavuconazonium sulfate) is the prodrug of isavuconazole, an azole antifungal drug. Isavuconazole inhibits the synthesis of ergosterol, a key component of the fungal cell membrane, through the inhibition of cytochrome P-450 dependent enzyme lanosterol 14-alpha-demethylase. This enzyme is responsible for the conversion of lanosterol to ergosterol. An accumulation of methylated sterol precursors and a depletion of ergosterol within the fungal cell membrane weakens the membrane structure and function. Mammalian cell demethylation is less sensitive to isavuconazole inhibition. 

    Additional Information

    For additional information regarding Cresemba or invasive aspergillosis and invasive mucormycosis, please visit https://www.cresemba.com/

    Approval Date: 2015-03-01
    Company Name: Astellas
    Back to Listings

    Upcoming Events

    • 27Jan

      Medical Device Clinical Trials in China: Latest Regulatory Developments

    • 11Feb

      Lab X.0: Addressing Quality and Compliance Challenges in Laboratory Operations in the COVID-19 All-Digital Era

    • 23Mar

      Data Integrity for GCP Professionals: Core Requirements, Expectations and Challenges

    • 26Apr

      MAGI's Clinical Research vConference — Spring 2021

    Featured Products

    • Regenerative Medicine – Steps to Accelerate Development : PDF

      Regenerative Medicine: Steps to Accelerate Development

    • Clinical Trial Agreements — A Guide to Key Words and Phrases : PDF

      Clinical Trial Agreements: A Guide to Key Words and Phrases

    Featured Stories

    • Resources-360x240.png

      Trial Complexity, Endpoints Continue to Increase, Stretching Site Resources

    • FocusinRed-360x240.png

      Return to Focus on Risk Management Postpandemic Could Prove Challenging to Sites

    • VaccinewithNeedle-360x240.png

      2021 Vaccine Industry Will Continue to be Dominated by COVID-19 Trials, Experts Say

    • Dominate-360x240.png

      COVID-19, Oncology, CNS and Infectious Disease Trials Will Dominate in 2021, Survey Predicts

    Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

    The information you need to adapt your monitoring plan to changing times.

    Learn More Here
    • About Us
    • Contact Us
    • Privacy Policy
    • Do Not Sell My Personal Information

    Footer Logo

    300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

    Phone 617.948.5100 – Toll free 866.219.3440

    Copyright © 2021. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing